Gilead Sciences, Inc.
Close on Nov 3, 2026Market cap $207.66BP/E –Yield 1.89%
Gilead Sciences Other Liver Disease by Year
Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) ($M) ($M)
Gilead Sciences Other Liver Disease: $874M in FY2025, up 87.2% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 874 | +87.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 467 | +21.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 385 | -9.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 426 | – | Form 10-K (filed 2025-02-28) ↗ |
Breakdown
What makes up other Liver Disease
- Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — U.S. sales ($M)476 · FY2025
- Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Europe sales ($M)330 · FY2025
- Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Rest of World sales ($M)69 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Other Liver Disease ($M), annual FY2022–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-other
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.
See a number that looks wrong?